SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

USRM RSS Feed
Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: TheHungryHippo, Papa Bear, BluSkies, StaleyCornell, buythebuy, mtlebomac
Search This Board: 
Last Post: 4/25/2017 1:56:02 AM - Followers: 828 - Board type: Free - Posts Today: 6



http://us-stemcell.com/en/home-2/





 

A COMMITMENT TO EXCELLENCE

Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 

 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.

 

.

Management:

Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
 
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.
 

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.
 

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame
 

 

Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director
     

 



Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
     
     

     
    
USRM - Daily Candlesticks






 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
USRM News: Significant Updates on the Following Companies and New Coverage 04/20/2017 09:00:00 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:49:04 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:47:59 AM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/31/2017 04:02:24 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/17/2017 04:02:15 PM
PostSubject
#52397  Sticky Note This is the guy who is investing up Vita Nova Stocks 04/15/17 09:22:22 AM
#42457  Sticky Note THIS IS A MUST READ slam4202 03/30/17 07:05:37 AM
#42449  Sticky Note CEO BLOG / FDA "On regulatory news, BluSkies 03/30/17 04:51:30 AM
#26891  Sticky Note $USRM ALL IN ONE DD Post for Investors: TheHungryHippo 03/09/17 05:25:50 AM
#26168  Sticky Note Thoughts? http://3030health.libsyn.com/episode-06-an-interview-with-kristin-com BluSkies 03/07/17 09:49:57 PM
#54812   Ooooh look shiny. Lol BearDickPunch 04/25/17 01:56:02 AM
#54811   I like....,,,,,$$$$$ usrm$$$$$$$$$ Luckydogs2017 04/25/17 01:34:03 AM
#54810   100% agree. Just look at how docprep 04/25/17 01:13:06 AM
#54809   The Jeopardy theme music has been playing in Track 04/25/17 12:16:05 AM
#54808   Two weeks ago JimboPMCB 04/25/17 12:01:21 AM
#54807   Provided additional information end of March clock reset. shaman919 04/25/17 12:01:18 AM
#54806   Does anyone have an estimate days remaining until Cdizz123 04/24/17 11:50:51 PM
#54805   The fact is that the credit line hasn't tqipres 04/24/17 11:44:36 PM
#54804   TY, I learned something which is always good. $USRM 11JR11 04/24/17 11:27:24 PM
#54803   who else on the OTC has a budding damain22 04/24/17 11:09:11 PM
#54802   Thank you, was driving me nuts. Thought it shaman919 04/24/17 11:00:30 PM
#54801   Going up* TradeUptrendz 04/24/17 10:56:37 PM
#54800   Adding more shares soon Tagprofenrir 04/24/17 10:56:22 PM
#54799   Stem cell clinics should be good up soon also:) TradeUptrendz 04/24/17 10:55:51 PM
#54798   Hard not to, I can't believe anyone is TradeUptrendz 04/24/17 10:55:22 PM
#54797   preach! damain22 04/24/17 10:54:24 PM
#54796   Bro, sit back and relax! I can see TradeUptrendz 04/24/17 10:51:54 PM
#54795   Im a second year pharmacy student in colorado damain22 04/24/17 10:50:56 PM
#54794   Yeah great trade opp a couple weeks ago, TradeUptrendz 04/24/17 10:49:12 PM
#54793   Could this take a bit to play out TradeUptrendz 04/24/17 10:47:27 PM
#54792   Lol he must be guessing, the draw price TradeUptrendz 04/24/17 10:46:10 PM
#54791   correct, so if you assume they did rush damain22 04/24/17 10:43:52 PM
#54790   I hope you're right. I'm holding... Just gotta Chicagojosh 04/24/17 10:43:47 PM
#54789   USRM chart(s) No confirmation on trigger chart yet. tothe 04/24/17 10:40:32 PM
#54788   It was announced on April 10th (news section Deal McMogulson 04/24/17 10:32:41 PM
#54787   lol, too much technicals n not enough common sense. emit 04/24/17 10:32:21 PM
#54786   That means any day till May 13. We Karma11 04/24/17 10:31:24 PM
#54785   Can't find it but I thought I read shaman919 04/24/17 10:15:32 PM
#54784   FDA by May 27th - On January 27, ShadyMaguire 04/24/17 10:15:16 PM
#54779   CEO's blog post on March 13 mentioned application trademax42 04/24/17 09:21:55 PM
#54778   We'll be hearin from the ole FDA within Havoc23 04/24/17 09:18:38 PM
#54777   The word on approval or denial will come dough11 04/24/17 08:58:59 PM
#54776   up to 60 days lol doesn't mean in 11JR11 04/24/17 08:57:26 PM
#54775   looking forward to positive news $USRM - could FutureBankruptcy 04/24/17 08:55:46 PM
#54773   Good luck, It's getting harder and harder to sdave2002 04/24/17 08:54:30 PM
#54772   Major bullish reversal imo fwiw $ABBY 11JR11 04/24/17 08:53:31 PM
#54771   You will be the 4th one. Chupacabras 04/24/17 08:47:28 PM
#54770   "There not putting up anything, it's a verbal sdave2002 04/24/17 08:46:06 PM
#54768   Love to see all you guys wanting cheaper MyzStreet 04/24/17 08:38:10 PM
#54767   It will get lower on till next month. Chupacabras 04/24/17 08:26:19 PM
#54766   Hard to resist these low prices here. Will BB Player 04/24/17 08:14:59 PM
#54765   I am also very surprised this hasn't climbed Rubyt 04/24/17 08:04:04 PM
#54764   Not to mention the $2.5 million towards opening shaman919 04/24/17 07:56:57 PM
#54763   Only thing that surprises me is the fact dough11 04/24/17 07:56:16 PM
#54762   Yes I remember then broke new high of.18 tamtam84 04/24/17 07:55:36 PM
#54761   It's not consolidation it's people holding because of dough11 04/24/17 07:55:01 PM
#54760   I am so ready for this product to tamtam84 04/24/17 07:52:15 PM
#54759   Text book consolidation, big Boom coming$$$$ TooYoungToDie 04/24/17 07:49:38 PM
#54758   This reminds me of when we were in Havoc23 04/24/17 07:47:57 PM
#54757   I bought more with 7's dip with blog tamtam84 04/24/17 07:45:27 PM
PostSubject